Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Perform | Oppenheimer | |
| 1/21/2025 | $186.00 | Perform → Outperform | Oppenheimer |
| 1/6/2025 | $139.00 | Neutral → Sell | Goldman |
| 9/12/2024 | $156.00 | Equal Weight | Wells Fargo |
| 4/11/2024 | $115.00 | Overweight → Neutral | JP Morgan |
| 1/11/2024 | Outperform → Perform | Oppenheimer | |
| 5/26/2023 | $87.00 | Perform → Outperform | Oppenheimer |
| 3/15/2023 | $85.00 | Neutral → Overweight | JP Morgan |
The global evergreen fund for secondaries investment seeks to offer a diversified portfolio of mature private equity investments positioned for value creation by leveraging the firm's 24+ years of experience in the secondary market and extensive scaleThis launch marks the 10th fund in Hamilton Lane's $12 billion+ AUM evergreen platformLONDON, Sept. 3, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (NASDAQ:HLNE) today announced the launch of the Hamilton Lane Global Private Secondary Fund ("HLGPS" or "the Fund"), an evergreen investment vehicle focused on the secondary market. The Fund is available to accredited high-net-worth investors and their advisors, as well
CONSHOHOCKEN, Pa., Sept. 2, 2025 /PRNewswire/ -- Private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) ("Hamilton Lane") today announced the pricing of an underwritten public offering by Hamilton Lane and a selling stockholder of 528,705 shares of Class A common stock, in the aggregate, for gross proceeds of approximately $77.5 million. The offering is expected to close on September 4, 2025, subject to customary closing conditions. Hamilton Lane intends to use the proceeds from the sale of its shares to settle in cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain of its members. Hamilton Lane will not receive any proceeds from the s
CONSHOHOCKEN, Pa., Sept. 2, 2025 /PRNewswire/ -- Private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) ("Hamilton Lane") today announced that it has commenced an underwritten public offering of 528,705 shares of Class A common stock, in the aggregate, to be sold by Hamilton Lane and a selling stockholder, subject to market and other conditions. Hamilton Lane intends to use the proceeds from the sale of its shares to settle in cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain of its members. Hamilton Lane will not receive any proceeds from the sale of shares by the selling stockholder. Accordingly, Hamilton Lane will not retain any
4 - Hamilton Lane INC (0001433642) (Issuer)
Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00
Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00
8-K - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
424B5 - Hamilton Lane INC (0001433642) (Filer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
-- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co
Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I
Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo
CONSHOHOCKEN, Pa., Aug. 5, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the first fiscal quarter ended June 30, 2025. The Company issued a full detailed presentation of its first quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/ Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on September 19, 2025 that will be paid on October 6, 2025. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year
CONSHOHOCKEN, Pa., July 15, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the first fiscal quarter ended June 30, 2025 before the market opens on Tuesday, August 5, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on August 5 to discuss the results for the first fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least 15 minut
CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)